Requests similar to 'MHRA and Bill Gates grants'

Response by Medicines and Healthcare Products Regulatory Agency to ANNA Frances on 5 May 2021.

Information not held

FOI 21/357 Dear AMCBA, Thank you for your email of the 5 April where you have asked " Please disclose where the UK public may access the scientific i...

Test data and results for each batch of BNT162b2 independently tested by the NIBSC under Regulation 174A

Response by Medicines and Healthcare Products Regulatory Agency to Dr Lee Proctor on 14 February 2023.

Awaiting classification

FOI 23/051 Dear Dr Lee Proctor, Thank you for your email. Please find attached the response to your FOI request. Kind Regards...

Fatalities from Covid19 vaccines

Response by Medicines and Healthcare Products Regulatory Agency to ANNA Frances on 7 April 2021.

Successful

Our Ref: FOI 21/356 Dear AMCBA, RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000 Thank you for your enquiry which we received on 6 April 20...

Correspondence with MHRA

Response by Commission on Human Medicines to D Jackson on 23 August 2022.

Successful

Our Ref: FOI 22/605 Dear Mr/Ms Jackson, Please see the attached response to your enquiry. Kind Regards, MHRA...

Bill Gates funding to Prime Minister et al

Request sent to Prime Minister's Office by ANNA Frances on 5 April 2021.

Information not held

Dear Prime Minister's Office, Please kindly provide written and digital documentation and all records off all funds received by the British Governmen...

Are PCR and Rapid tests are diagnostic for active disease and transmission?

Response by Medicines and Healthcare Products Regulatory Agency to Katon bouzalakos on 19 February 2024.

Partially successful

Dear Katon Bouzalakos Your request FOI 23/902 and your two subsequent emails of 19/12/2023 were submitted to us through different whatdotheyknow...

Why these tests, being unable to discriminate the alive/active viruses from the dead/nonactive, are used in detection of covid19 disease (which is an active condition)

Response by Medicines and Healthcare Products Regulatory Agency to Katon bouzalakos on 19 February 2024.

Information not held

Dear Katon Bouzalakos Your request FOI 23/902 and your two subsequent emails of 19/12/2023 were submitted to us through different whatdotheyknow...

What genomic sequence the PCR test is looking for, to determine if a person is positive with covid 19 ?

Response by Medicines and Healthcare Products Regulatory Agency to Katon bouzalakos on 16 November 2023.

Refused

FOI 23/797 Dear Katon Thank you for your email correspondence with our FOI team on 17 October 2023, where you submitted an FOI request for the follow...

Reports and Data to meet Conditions of Authorisation for Vaxzevria

Response by Medicines and Healthcare Products Regulatory Agency to CHP Gillow on 22 July 2023.

Partially successful

Dear CHP Gillow Please find attached 4 disclosure documents for Question 3 of request for Conditions of Authorisation for Vaxzevria, request FOI...

Safety signal reporting for Pfizer/BioNTech Covid 19 Vaccine

Response by Medicines and Healthcare Products Regulatory Agency to Mr B Kingsley on 9 August 2023.

Partially successful

FOI 23/474 Dear Mr B Kingsley Thank you for your email. Please find attached the response and documentation to your FOI request. Kind Regards MHR...

Minutes of February Board Meeting

Response by Medicines and Healthcare Products Regulatory Agency to Gary Marshall on 27 April 2022.

Successful

FOI 22/635 and FOI 22/636 Dear Mr Marshall, Thank you for your email requesting the MHRA Board minutes from February and March. The Februa...

Board Meeting Minutes - March 2022

Response by Medicines and Healthcare Products Regulatory Agency to Gary Marshall on 27 April 2022.

Information not held

FOI 22/635 and FOI 22/636 Dear Mr Marshall, Thank you for your email requesting the MHRA Board minutes from February and March. The Februa...

Isolation document of Covid 19 and Ingredients of Pfizer vaccine

Response by Medicines and Healthcare Products Regulatory Agency to ANNA Frances on 4 January 2021.

Partially successful

FOI 20/576 Dear Anna Frances, Thank you for your email. The list of ingredients in the Pfizer/BioNTech vaccine is available in the Informa...

Origination of Biotechnology, Biotechnology Companies and Vaccines,

Response by Medicines and Healthcare Products Regulatory Agency to Dominique Anderson on 3 February 2021.

Information not held

Dear Dominique Anderson, Thank you for your emails below and attached. The authorisation of the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines...

sage board and funding from the Gates Foundation

Response by Medicines and Healthcare Products Regulatory Agency to Ricci on 28 March 2022.

Information not held

FOI 22/576 Dear Ricci, Thank you for your email 23rd March where you have asked " Could you please confirm weather or not and of the board members of...

Delta Variant Testing

Response by UK Health Security Agency to Ann McNeil on 11 November 2021.

Partially successful

Dear Ann McNeil, Please find attached the UK Health Security Agency's response to your request. The UK Health Security Agency (UKHSA) has taken res...

Immune system's response to pathogens following COVID-19 vaccination

Response by Medicines and Healthcare Products Regulatory Agency to Kenneth MacArthur on 26 October 2021.

Refused

Internal Review of FOI 21/550 Dear Mr MacArthur, Unfortunately, due to the number of Freedom of Information (FOI) requests we have been re...

Contents of all the vaccines being used for Covid and the variants in England and Wales.

Response by Medicines and Healthcare Products Regulatory Agency to Jane McDonnell on 23 January 2022.

Information not held

Thank you for your email. This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...

Covid vaccine safety

Response by Medicines and Healthcare Products Regulatory Agency to Bethany Green on 2 February 2021.

Awaiting classification

FOI 21/007 Dear Bethany Green, Thank you for your email dated 4th January 2021 where you requested information about adverse drug reactions (ADR) to...

Definition of "Emergency Use"

Response by Medicines and Healthcare Products Regulatory Agency to Roland Gilmore on 25 December 2021.

Refused

Thank you for your email. This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...

Minutes of meeting to approve c19 Astrazeneca vaccine

Response by Medicines and Healthcare Products Regulatory Agency to vikki spit on 17 February 2022.

Partially successful

FOI 22/453 Dear Vikki Spit, Thank you for your email. The decision to grant a marketing authorisation for the AstraZeneca vaccine wa...

Unblinding of vaccine trials

Response by Medicines and Healthcare Products Regulatory Agency to J. Mwanzia on 5 October 2023.

Waiting clarification

FOI 23/569 Dear J. Mwanzia, Thank you for your request for information dated, Saturday 5 August 2023, where you asked: “In your resp...

Section 3.2.P.1 for all approved COVID-19 vaccines

Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on 1 September 2023.

Awaiting classification

Dear Mr Weissman, Thank you for your request dated 10 March 2023, we apologise for the long delay in response. As you know, during the han...

Does the MHRA outsource investigation of YELLOW CARD suspected side effects to the pharmaceutical company that makes the product?

Response by Medicines and Healthcare Products Regulatory Agency to Adam Banks on 13 April 2022.

Partially successful

Thank you for your email. This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...

US DoD Medical Countermeasures

Response by Medicines and Healthcare Products Regulatory Agency to Dan Couzens on 13 August 2024.

Successful

Dear Mr Couzens Apologies for the delay in sending this to you. However, please see attached our internal review for FOI 23/047. Best regards MH...